Back to search results

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Abroad (travel likely)RecruitingPHASE3

Conditions

Palmoplantar Pustulosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Ppp001 50754, Birmingham, Alabama, United States

  • Ppp001 50746, Coral Gables, Florida, United States

  • Ppp001 50757, Auburn Hills, Michigan, United States

  • Ppp001 50745, Columbus, Ohio, United States

  • Ppp001 50202, Fairborn, Ohio, United States

  • Ppp001 50744, Oklahoma City, Oklahoma, United States

  • Ppp001 50233, Barrie, Canada

  • Ppp001 50354, Calgary, Canada

  • Ppp001 50749, Fredericton, Canada

  • Ppp001 50765, London, Canada

  • Ppp001 50740, Québec, Canada

  • Ppp001 50752, Red Deer, Canada

  • Ppp001 50750, Surrey, Canada

  • Ppp001 20357, Beijing, China

  • Ppp001 20137, Chengdu, China

  • Ppp001 20352, Chengdu, China

  • Ppp001 20350, Chongqing, China

  • Ppp001 20311, Guangzhou, China

  • Ppp001 20313, Guangzhou, China

  • Ppp001 20022, Hangzhou, China

  • Ppp001 20193, Hangzhou, China

  • Ppp001 20344, Jinan, China

  • Ppp001 20355, Jinan, China

  • Ppp001 20345, Shanghai, China

  • Ppp001 20184, Shenzhen, China

  • Ppp001 20136, Tianjin, China

  • Ppp001 20356, Xi'an, China

  • Ppp001 20353, Yinchuan, China

  • Ppp001 40881, Ústí nad Labem, Czechia

  • Ppp001 40886, Hellerup, Denmark

  • Ppp001 40067, Lyon, France

  • Ppp001 40874, Nice, France

  • Ppp001 40887, Toulon, France

  • Ppp001 40875, Ahaus, Germany

  • Ppp001 40740, Bad Bentheim, Germany

  • Ppp001 40515, Berlin, Germany

  • Ppp001 40891, Bielefeld, Germany

  • Ppp001 40893, Bochum, Germany

  • Ppp001 40356, Dresden, Germany

  • Ppp001 40866, Göttingen, Germany

  • Ppp001 40249, Kiel, Germany

  • Ppp001 40892, Lübeck, Germany

  • Ppp001 40747, Mainz, Germany

  • Ppp001 40177, Münster, Germany

  • Ppp001 40366, Rostock, Germany

  • Ppp001 40203, Budapest, Hungary

  • Ppp001 40895, Debrecen, Hungary

  • Ppp001 40894, Orosháza, Hungary

  • Ppp001 40816, Brescia, Italy

  • Ppp001 40567, Roma, Italy

  • Ppp001 40830, Rozzano, Italy

  • Ppp001 40626, Bialystok, Poland

  • Ppp001 40637, Gdansk, Poland

  • Ppp001 40878, Katowice, Poland

  • Ppp001 40915, Krakow, Poland

  • Ppp001 40625, Lodz, Poland

  • Ppp001 40757, Poznan, Poland

  • Ppp001 40396, Rzeszów, Poland

  • Ppp001 40743, Szczecin, Poland

  • Ppp001 40788, Torun, Poland

  • Ppp001 40604, Warsaw, Poland

  • Ppp001 40876, Warsaw, Poland

  • Ppp001 40334, Wroclaw, Poland

  • Ppp001 40862, Wroclaw, Poland

  • Ppp001 20366, Anyang-si, South Korea

  • Ppp001 20211, Bucheon-si, South Korea

  • Ppp001 20214, Busan, South Korea

  • Ppp001 20215, Gwangju, South Korea

  • Ppp001 20367, Jeonju, South Korea

  • Ppp001 20208, Seongnam-si, South Korea

  • Ppp001 20104, Seoul, South Korea

  • Ppp001 20216, Seoul, South Korea

  • Ppp001 20220, Seoul, South Korea

  • Ppp001 20351, Seoul, South Korea

  • Ppp001 20354, Seoul, South Korea

  • Ppp001 40750, Alicante, Spain

  • Ppp001 40266, Badalona, Spain

  • Ppp001 40885, Granada, Spain

  • Ppp001 40888, Madrid, Spain

  • Ppp001 40297, Manises, Spain

  • Ppp001 40889, Málaga, Spain

  • Ppp001 40879, Santiago de Compostela, Spain

  • Ppp001 40230, Valencia, Spain

  • Ppp001 40868, Valencia, Spain

  • Ppp001 40113, London, United Kingdom

  • Ppp001 40880, London, United Kingdom

  • Ppp001 40108, Salford, United Kingdom

Study leads

  • UCB Cares

    Study Director

    001 844 599 22733 (UCB)

View source on ClinicalTrials.gov(opens in a new tab)